时间：2016-9-19（周一）15：00 - 16：00

地点：生命学院大会议室

报告人：Min He, Ph.D, National Cancer Institute, National Institute of Health

报告题目：To be or not to be: natural products drug discovery (天然产物药物开发：困境与前景)

Min He, Ph.D.

Special Assistant to the Associate Director

Developmental Therapeutics Program

National Cancer Institute

National Institute of Health

Dr. He received a B.S. in Microbiology from Sichuan University and a Ph.D. in Microbiology and Molecular Biology from University of Minnesota. She joined Wyeth (now part of Pfizer) in 2001 as a senior scientist and then rose to principle scientist. There, she was heavily invested in high throughput screens of natural products library for various therapeutic indications and structural modification of natural product drug candidates through biosynthetic pathway reprogramming and metabolic engineering. She also initiated the discovery of potent pan--‐PIKK inhibitors and spliceosome inhibitors that were later developed as the warhead for antibody--‐drug conjugate for cancer treatment.

Dr. He joined the National Cancer Institute (NCI) in 2010 as the Special Assistant to the Associate Director of the Developmental Therapeutics Program (DTP). Her main duties include coordinating activities cross the program to expedite the discovery and pre--‐clinical development of new anti--‐cancer therapeutic agents, as well as serving as scientific liaison with extramural investigators and sister programs in NCI to facilitate various research collaborations and grants activities.

Dr. He has publications on various aspects of natural products biosynthesis and drug discovery, and holds 6 patents.